Log In Sign Up

The front door to your Biohub.

BioBuzz connects 30,000+ life sciences professionals with hundreds of companies, thousands of jobs, and every event worth knowing — and the community you’ve been looking for, right in your backyard.

Sign In →

Find Your Next Career Move

Browse 2,500+ active life sciences jobs across biotech, pharma, medtech, and more. Let AI match you with roles you’ll love.

Browse Jobs →

Build Your Network in Life Sciences

Access 200+ curated events annually. Connect with researchers, executives, innovators and investors across every sector of life sciences.

Explore Events →
BioHealth Capital Region

BioHealth Capital Region

Maryland, D.C., and Virginia — one of the largest life science corridors in the U.S.

Explore →
Greater Philadelphia

Greater Philadelphia

Philadelphia, South Jersey, and Delaware — a powerhouse of pharma and biotech innovation.

Explore →
Research Triangle Park

Research Triangle Park

North Carolina's Research Triangle — a growing hub for biotech and life sciences.

Explore →

Featured News

Xcellon Acquires 40,000 Sq ft Maryland Facility from NextCure to Deliver a cGMP-Ready CRDMO for ADCs
BioHealth Capital Region Real Estate

Xcellon Acquires 40,000 Sq ft Maryland Facility from NextCure to Deliver a cGMP-Ready CRDMO for ADCs

Xcellon Biologics, a Maryland CRDMO specializing in bioconjugates and complex biologics, has signed a definitive agreement to acquire the GMP biologics manufacturing facility built by NextCure, Inc. in Beltsville. The deal gives Xcellon its first cGMP capacity, completes the company’s transition from a development-stage CDMO into an end-to-end CRDMO, and puts a commissioned domestic bioconjugation […]

Read More →

Our Partners

Fulton Bank Heffron Company Kymanox Ledgermark Minaris Advanced Therapies Pharmaron PQE Group TEDCO Workforce Genetics BaneBio BioTrain Bio-Trac CRB Conner Strong & Buckelew ETC Frederick County Frederick City

Latest News

North CarolinaIndustry TrendsResearch

Cary’s Veloxis Pharmaceuticals to Be Folded Into New “Asahi Kasei Therapeutics” Global Brand

Asahi Kasei announced on September 29, 2026 that Veloxis Pharmaceuticals, headquartered in Cary, North Carolina, will be integrated alongside Asahi Kasei Therapeutics (Japan), Calliditas Therapeutics (Sweden), and the recently acquired AiCuris Anti-infective Cures (Germany) under a single unified global brand: Asahi Kasei Therapeutics. The move establishes one global management structure for Asahi Kasei’s pharmaceutical business […]

Greater PhiladelphiaIndustry TrendsResearch

Merck Enters $2.13 Billion License Deal With SciBrunch for Preclinical KRAS G12D Inhibitor

Merck, known as MSD outside the U.S. and Canada, and Shanghai-based SciBrunch Therapeutics announced on September 28, 2026 an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor. Under the deal, SciBrunch grants Merck exclusive worldwide rights to develop, manufacture, and commercialize SPR2015; the transaction has already closed.  George Addona, […]

BioHealth Capital RegionIndustry TrendsPeople

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

QIAGEN N.V. headquartered in Venlo, Netherlands with a major U.S. base in Germantown, Maryland, announced on September 28, 2026 that U.S. laboratories now have access to its complete QIAstat-Dx bloodstream infection portfolio, following FDA clearance of a new panel that detects gram-negative bacteria and antibiotic resistance markers in about one hour. The new QIAstat-Dx BCID […]

BioHealth Capital RegionPeopleResearch

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026

IGC Pharma, Inc. a Potomac, Maryland-based clinical-stage biotechnology company, announced on September 28, 2026 that it has completed enrollment in its CALMA Phase 2 trial evaluating lead asset IGC-AD1 for agitation in Alzheimer’s dementia. CALMA achieved target enrollment with 168 participants randomized, including planned over-enrollment designed to strengthen the evaluable dataset for end-of-treatment, secondary, and […]

Greater PhiladelphiaFundingPolicy

Earendil Labs Announces Research Collaboration with Genentech to Discover and Develop Therapeutic Bispecific Antibodies

Earendil Labs, a Wilmington, Delaware-based AI-powered biotechnology company, announced on September 24, 2026 a research collaboration with Genentech, a member of the Roche Group, to discover and develop multiple therapeutic bispecific antibody programs in oncology. Under the deal, Earendil will lead antibody discovery and research through early clinical development for programs directed at pre-agreed target […]

BioHealth Capital RegionIndustry TrendsPolicy

HHS and EPA Announce New Scientific Partnership to Strengthen Glyphosate Review

The U.S. Department of Health and Human Services (HHS) and the U.S. Environmental Protection Agency (EPA) announced a new interagency Memorandum of Understanding on September 22, 2026 to strengthen scientific coordination and expand the evidence available to EPA’s ongoing registration review of glyphosate under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Under the MOU, […]

Greater PhiladelphiaIndustry TrendsPress Release

Minaris Adds Dedicated Viral Vectors Business Unit, Splitting Into Three Specialized Divisions 

Minaris, the Philadelphia-based global cell and gene therapy CDMO and multimodal contract testing organization, announced on September 29, 2026 the addition of a dedicated Viral Vectors business unit, evolving its business model around three specialized areas: Cell Therapies, Viral Vectors, and Advanced Testing.  CEO Orla Cloak said: “Minaris is entering its next phase with a […]

Greater PhiladelphiaIndustry TrendsResearch

Peptide Therapeutics Are Entering a New Phase. The Analytical Lab Has to Keep Up.

At the recent Biopharma Analytical Innovation Summit in Malvern, analytical scientists examined the solubility, impurity, and sensitivity challenges that come with a growing wave of peptide drugs, and how lab workflows are adapting to meet them. Peptide therapeutics spent decades as a specialized corner of drug development. GLP-1 receptor agonists changed that, and the effect […]

Greater PhiladelphiaIndustry Trends

Tolerance Bio Lands Second Clinical Deal, Building the Broadest Clinical-Stage Thymus Pipeline

Key Highlights Every person’s thymus, the organ that trains the immune system, shrinks with age, and as it fades the body becomes more vulnerable to infection, cancer and autoimmune disease. Tolerance Bio has now secured what it calls the broadest pipeline aimed at slowing, stopping and reversing that loss. The Philadelphia biotech has licensed TLB-33, […]

Upcoming Events

Sep 30
Conference

Biocom’s HR Conference for Life Science

San Diego, CA

View Event →
Sep 30

Introduction to Biopharma Manufacturing 9/30

BioHealth Capital Region
Sep 30

International Clinical Cytometry Society Annual Meeting
Sep 30

Life Sciences Future

Greater Philadelphia
Sep 30

Introduction to Biopharma Manufacturing

BioHealth Capital Region
Sep 30

Oktoberfest Celebration Happy Hour and Networking

Greater Philadelphia
View All Events →

Programs & Services

Digital Media + Advertising

Events + Sponsorship

BioCatalyst · A BioBuzz Workforce Initiative

Talent Solutions

Recruitment marketing and employer branding services tailored for…
View All Programs & Services →

Stay in the Loop

Get the latest life science news delivered to your inbox weekly.